{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable at the time of analysis due to the low number of events","groupId":"OG000","lowerLimit":"19.2","upperLimit":"NA","value":"36.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"116"}],"units":"Participants"}],"description":"Overall survival was measured from the first treatment with blinatumomab until death due to any cause. Participants who did not die were censored at their last contact date.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinatumomab as a continuous intravenous infusion at a constant flow rate of 15 μg/m²/day over 28 days followed by an infusion-free period of 14 days for up to 4 cycles of treatment.","id":"OG000","title":"Blinatumomab"}],"paramType":"MEDIAN","populationDescription":"Full analysis set","reportingStatus":"POSTED","timeFrame":"Until the data cut-off date of 05 August 2015; median time on study was 18.3 months.","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"months"}